To test this hypothesis, we analyzed the association between the TP53 G/C-to-A/T mutation and APOBEC3B expression in clinical specimens from relapsed/refractory (R/R) DLBCL patients. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.